A Study of LG00313112 in Participants With Advanced Solid Malignancies Harboring a TP53 Y220C Mutation

NCT07752875 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

NOT_YET_RECRUITING

Status

250

Enrollment

INDUSTRY

Sponsor class

Conditions

Ovarian Cancer
Small Cell Lung Cancer
Non Small Cell Lung Cancer
Colorectal Cancer
Esophageal Cancer
Breast Cancer
Endometrial Cancer
Head and Neck Cancer
Pancreatic Cancer
Locally Advanced Unresectable or Metastatic Solid Tumor

Interventions

DRUG: LG00313112

Sponsor

LG Chem